Olivier M. Dorchies

Dr. Olivier M. Dorchies

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in The American Journal of Pathology
Verified
Journal Article
Open access
ODOlivier M. Dorchies
Olivier M. Dorchies
JRJulie Reutenauer-Patte
Julie Reutenauer-Patte
EDElyes Dahmane
Elyes Dahmane
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
OPOlivier Petermann
Olivier Petermann
URUrs T. RUEGG
Urs T. RUEGG
Duchenne muscular dystrophy (DMD) is a severe disorder characterized by progressive muscle wasting,respiratory and cardiac impairments, and premature death. No treatment exists so far, and the identification of active substances to fight DMD is urgently needed. We found that tamoxifen, a drug used to treat estrogen-dependent breast cancer, caused remarkable improvements of muscle force and of diaphragm and cardiac structure in the mdx(5Cv) mouse model of DMD. Oral tamoxifen treatment from 3 weeks of age for 15 months at a dose of 10 mg/kg/day stabilized myofiber membranes, normalized whole body force, and increased force production and resistance to repeated contractions of the triceps muscle above normal values. Tamoxifen improved the structure of leg muscles and diminished cardiac fibrosis by~ 50%. Tamoxifen also reduced fibrosis in the diaphragm, while increasing its thickness,myofiber count, and myofiber diameter, thereby augmenting by 72% the amount of contractile tissue available for respiratory function. Tamoxifen conferred a markedly slower phenotype to the muscles.Tamoxifen and its metabolites were present in nanomolar concentrations in plasma and muscles,suggesting signaling through high-affinity targets. Interestingly, the estrogen receptors ERa and ERb were several times more abundant in dystrophic than in normal muscles, and tamoxifen normalized the relative abundance of ERb isoforms. Our findings suggest that tamoxifen might be a useful therapy for DMD.

19 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGElinam Gayi
Elinam Gayi
LNLaurence Neff
Laurence Neff
XMXènia Massana Muñoz
Xènia Massana Muñoz
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
MSMarta Sierra
Marta Sierra
LSLeonardo Scapozza
Leonardo Scapozza
X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by generalized hypotonia, leading to neonatal death of most patients. No specific treatment exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues the phenotype of Mtm1-deficient mice. Tamoxifen increases lifespan several-fold while improving overall motor function and preventing disease progression including lower limb paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM, with improved force output, myonuclei positioning, myofibrillar structure, triad number, and excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our findings demonstrate that tamoxifen is a promising candidate for clinical evaluation in XLMTM patients.

16 September 2015 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
PAPaula B. M. De Andrade
Paula B. M. De Andrade
LNLaurence Neff
Laurence Neff
MSMiriam K. Strosova
Miriam K. Strosova
DADenis Arsenijevic
Denis Arsenijevic
OPOphélie Patthey-Vuadens
Ophélie Patthey-Vuadens
ODOlivier M. Dorchies
Olivier M. Dorchies
Weight regain after caloric restriction results in accelerated fat storage in adipose tissue. This catch-up fat phenomenon is postulated to result partly from suppressed skeletal muscle thermogenesis, but the underlying mechanisms are elusive. We investigated whether the reduced rate of skeletal muscle contraction-relaxation cycle that occurs after caloric restriction persists during weight recovery and could contribute to catch-up fat. Using a rat model of semistarvation-refeeding, in which fat recovery is driven by suppressed thermogenesis, we show that contraction and relaxation of leg muscles are slower after both semistarvation and refeeding. These effects are associated with (i) higher expression of muscle deiodinase type 3 (DIO3) which inactivates tri-iodothyronine (T3), and lower expression of T3-activating enzyme, deiodinase type 2 (DIO2), (ii) slower net formation of T3 from its T4 precursor in muscles, and (iii) accumulation of slow fibers at the expense of fast fibers. These semistarvation-induced changes persisted during recovery and correlated with impaired expression of transcription factors involved in slow-twitch muscle development. We conclude that diminished muscle thermogenesis following caloric restriction results from reduced muscle T3 levels, alteration in muscle-specific transcription factors, and fast-to-slow fiber shift causing slower contractility. Energy-sparing effects persist during weight recovery and likely contribute to catch-up fat.

1 August 2021 in Molecular Therapy
Verified
Journal Article
Open access
SDSarah Djeddi
Sarah Djeddi
DRDavid Reiss
David Reiss
AMAlexia Menuet
Alexia Menuet
SFSébastien Freismuth
Sébastien Freismuth
JNJuliana de Carvalho Neves
Juliana de Carvalho Neves
JLJocelyn Laporte
Jocelyn Laporte
Omics analyses are powerful methods to obtain an integrated view of complex biological processes, disease progression, or therapy efficiency. However, few studies have compared different disease forms and different therapy strategies to define the common molecular signatures representing the most significant implicated pathways. In this study, we used RNA sequencing and mass spectrometry to profile the transcriptomes and proteomes of mouse models for three forms of centronuclear myopathies (CNMs), untreated or treated with either a drug (tamoxifen), antisense oligonucleotides reducing the level of dynamin 2 (DNM2), or following modulation of DNM2 or amphiphysin 2 (BIN1) through genetic crosses. Unsupervised analysis and differential gene and protein expression were performed to retrieve CNM molecular signatures. Longitudinal studies before, at, and after disease onset highlighted potential disease causes and consequences. Main pathways in the common CNM disease signature include muscle contraction, regeneration and inflammation. The common therapy signature revealed novel potential therapeutic targets, including the calcium regulator sarcolipin. We identified several novel biomarkers validated in muscle and/or plasma through RNA quantification, western blotting, and enzyme-linked immunosorbent assay (ELISA) assays, including ANXA2 and IGFBP2. This study validates the concept of using multi-omics approaches to identify molecular signatures common to different disease forms and therapeutic strategies.

1 April 2018 in Chimia
Verified
Journal Article
Open access
EGElinam Gayi
Elinam Gayi
LNLaurence A. Neff
Laurence A. Neff
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
URUrs T. Ruegg
Urs T. Ruegg
LSLeonardo Scapozza
Leonardo Scapozza
ODOlivier M. Dorchies
Olivier M. Dorchies
Drug discovery is a long, expensive and risky process. Evaluating drugs that have already been proved safe for use in humans and testing them for a new indication greatly reduces the time and monetary costs involved in finding treatments for life-threatening conditions. Here tamoxifen, a drug that is used for the treatment of breast cancer, is investigated in a mouse model of Duchenne muscular dystrophy. Tamoxifen was efficacious in countering the symptoms of the disease without affecting the underlying genetic cause. Based on these results, tamoxifen has been tested in other forms of muscle disease with success. Drug repurposing may not only be a cost-effective manner for treating a variety of diseases, it may also help us uncover common mechanisms between conditions that were previously thought to be unrelated.

1 March 2025 in Degenerative Neurological and Neuromuscular Disease
Verified
Journal Article
Open access
PDF file
HRH Lawrence Remmel
H Lawrence Remmel
SHSandra S Hammer
Sandra S Hammer
LNLaurence Neff
Laurence Neff
ODOlivier M. Dorchies
Olivier M. Dorchies
LSLeonardo Scapozza
Leonardo Scapozza
SQSteven C Quay
Steven C Quay
Duchenne Muscular Dystrophy (DMD) is an inherited, X-linked disorder that is progressive, debilitating, and ultimately fatal. The current therapeutic landscape offers no cures, but does include palliative treatments that delay disease progression, and there is progress on genetic therapies that have the promise to be curative. There is much room for new therapies, and foundational work with the estrogen receptor modulator tamoxifen suggests the potential of a unique spectrum of therapeutic benefit from endoxifen, a metabolite of tamoxifen. Here we describe the potential for this new DMD therapy in the context of the overall DMD therapeutic landscape.